





## Administration of RSV vaccines and monoclonal antibodies by age group or cohort

| Age group or cohort   | RSV vaccines for adults  |   | RSV monoclonal antibodies for infants  |  |
|---|--|---|--|--|
|   | Abrysvo® 0.5mL<br>(Pfizer)   | Arexvy® 0.5 mL<br>(GSK)   | Beyfortus™ (Nirsevimab) 0.5 mL<br>(Purple) (Sanofi)  | Beyfortus™ (Nirsevimab) 1 mL<br>(Blue) (Sanofi)  |
| Women from 28 weeks pregnancy   | <br><b>NIP FUNDED</b> | <br><b>DO NOT USE</b> | <br><b>DO NOT USE</b> | <br><b>DO NOT USE</b> |
| Infants & children ≤24 months   | <b>DO NOT USE</b>  | <b>DO NOT USE</b>   | <b>STATE &amp; TERRITORY FUNDED</b>  | <b>STATE &amp; TERRITORY FUNDED</b>  |
| Adults 60-74 years<br>Adults with medical conditions that increase risk of severe RSV | <b>AVAILABLE PRIVATELY BASED ON CLINICAL DECISION</b>  | <b>AVAILABLE PRIVATELY BASED ON CLINICAL DECISION</b>   | <b>DO NOT USE</b>  | <b>DO NOT USE</b>  |
| Adults ≥75 years<br>Aboriginal and Torres Strait Islander people ≥60 years            | <b>AVAILABLE PRIVATELY BASED ON CLINICAL DECISION</b>  | <b>NIP FUNDED</b>   | <b>DO NOT USE</b>  | <b>DO NOT USE</b>  |

**Note:** **NIP FUNDED** indicates vaccine is NIP funded. **DO NOT USE** indicates product is **NOT** recommended for that group. **STATE & TERRITORY FUNDED** indicates funded under a state and territory program. **AVAILABLE PRIVATELY** indicates product only available through private prescription and is not funded. For further information including dosage and administration, refer to the Australian Immunisation Handbook chapter – [Respiratory syncytial virus \(RSV\)](#)